2 active not recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow imetelstat: new trials by email Literature Review of imetelstat trials Research Report on imetelstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Imetelstat Sodium, Placebo - Myelodysplastic Syndromes | Phase 2 / Phase 3 | Active not recruiting | Geron Corporation | 289 | 2016-01-12 | 2026-07-17 |
Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Polycythemia (1) · Primary Myelofibrosis (1) · Recurrence (1) · Thrombocytosis (1)
Belgium (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Poland (2) · Russia (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1)
Joe Eid (1) · Tymara Berry, MD (1)
PMID 33108243, PMID 35510486, PMID 38048786, PMID 41135032, PMID 41568521
2015 (1), 2023 (1)